Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Bitdeer Technologies Group (BTDR) Price & Performance

Alnylam Pharmaceuticals, Inc.Trade
Bitdeer Technologies GroupTrade

Price performance (Past 24H)

Key statistics

Alnylam Pharmaceuticals, Inc. vs Bitdeer Technologies Group — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while Bitdeer Technologies Group trades at $9.02 (market cap $2.36B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 12.5× Bitdeer Technologies Group's market cap. Which is the better fit depends on your goals.

ALNYBTDR
Market Cap
$29.60B$2.36B
Sector
HealthTechnology
52-Week High
$491.22$25.90
52-Week Low
$205.48$7.28
Enterprise Value
$27.56B$3.85B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alnylam Pharmaceuticals, Inc.

ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.

Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.

Bitdeer Technologies Group

BTDR trades at $9.02, up 3.74% in the last session, with a bearish technical signal from moving averages and oscillators. The company reported Q2 2026 revenue of $812 million but a net loss of $229 million, missing EPS estimates for four consecutive quarters. Recent news highlights a $4.7 billion AI data center deal in Norway, expanding beyond Bitcoin mining, though gross margins remain pressured.

Outlook is mixed: strong analyst buy consensus (81.82%) and a $22.43 price target suggest upside, but persistent losses, negative cash flow from operations, and high dependency on volatile crypto markets pose significant risks. Investors should weigh growth potential in AI infrastructure against execution challenges and profitability concerns.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

Read more on ALNY

About Bitdeer Technologies Group

Bitdeer is a world-leading technology company for blockchain and high-performance computing. It provides comprehensive digital asset mining solutions, including cloud mining, hosting, and data center management.

Read more on BTDR